rolipram has been researched along with Pulmonary Disease, Chronic Obstructive in 18 studies
Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, we were interested in investigating its selectivity on PDE4 and binding ability on high-affinity rolipram-binding sites (HARBs) in vitro, and its effects on ovalbumin-induced airway hyperresponsiveness in vivo, and clarifying its potential for treating asthma and chronic obstructive pulmonary disease (COPD)." | 3.77 | Hesperetin-7,3'-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio. ( Chen, CM; Han, CY; Hsu, HT; Ko, WC; Wang, KH; Yang, YL, 2011) |
| " As this experimental model of lung inflammation partially mimics some features of chronic obstructive pulmonary disease (COPD), we have investigated the effects of treatment by anti-inflammatory compounds, dexamethasone and rolipram and a non-specific matrix metalloproteinase (MMP) inhibitor, marimastat." | 3.74 | Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. ( Berna, P; Bertrand, CP; Boichot, E; Hitier, S; Lagente, V; Nénan, S; Planquois, JM, 2007) |
| "Chronic obstructive pulmonary disease (COPD) is a common, progressive respiratory disease that causes great morbidity and mortality despite treatment." | 2.71 | The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients. ( Belleguic, C; Bertrand, C; Brinchault, G; Depincé, A; Lagente, V; Leportier-Comoy, C; Martin-Chouly, CA; Ouagued, M; Pruniaux, MP, 2005) |
| "Theophylline is a difficult drug to use clinically, requiring careful titration and routine plasma monitoring due to the risk of toxic side effects, such as cardiovascular and central nervous system adverse events, with dose adjustments required in many patients, including smokers, the elderly and some patients on concomitant medications." | 2.42 | PDE4 inhibitors in COPD--a more selective approach to treatment. ( Vignola, AM, 2004) |
| "Tobacco smoke-induced chronic obstructive pulmonary disease (COPD) is a prolonged inflammatory condition of the lungs characterized by progressive and largely irreversible airflow limitation attributable to a number of pathologic mechanisms, including bronchitis, bronchiolitis, emphysema, mucus plugging, pulmonary hypertension, and small-airway obstruction." | 1.38 | Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease. ( Dong, H; Guo, L; Hammock, BD; Pinkerton, KE; Uyeminami, D; Wang, L; Yang, J, 2012) |
| "The etiology of chronic obstructive pulmonary disease (COPD) is complex and involves an aberrant inflammatory response." | 1.38 | Attenuation of inhibitory prostaglandin E2 signaling in human lung fibroblasts is mediated by phosphodiesterase 4. ( Basma, H; Fahrid, M; Gunji, Y; Holz, O; Kanaji, N; Liu, X; Magnussen, H; Michalski, J; Muller, KC; Nakanishi, M; Nelson, A; Nogel, S; Rabe, KF; Rennard, SI; Sato, T; Toews, ML; Wang, X, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (61.11) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kodimuthali, A | 1 |
| Jabaris, SS | 1 |
| Pal, M | 1 |
| Song, G | 1 |
| Zhu, X | 1 |
| Li, J | 1 |
| Hu, D | 1 |
| Zhao, D | 1 |
| Liao, Y | 1 |
| Lin, J | 1 |
| Zhang, LH | 2 |
| Cui, ZN | 2 |
| Hu, DK | 1 |
| Zhao, DS | 1 |
| He, M | 1 |
| Jin, HW | 1 |
| Tang, YM | 1 |
| Song, GP | 1 |
| Dunne, AE | 1 |
| Kawamatawong, T | 1 |
| Fenwick, PS | 1 |
| Davies, CM | 1 |
| Tullett, H | 1 |
| Barnes, PJ | 1 |
| Donnelly, LE | 1 |
| Schymeinsky, J | 1 |
| Mayer, H | 1 |
| Tomsic, C | 1 |
| Tilp, C | 1 |
| Schuetz, JD | 1 |
| Cui, Y | 1 |
| Wollin, L | 1 |
| Gantner, F | 1 |
| Erb, KJ | 1 |
| Yang, YL | 1 |
| Hsu, HT | 1 |
| Wang, KH | 1 |
| Han, CY | 1 |
| Chen, CM | 2 |
| Ko, WC | 1 |
| Wang, L | 1 |
| Yang, J | 1 |
| Guo, L | 1 |
| Uyeminami, D | 1 |
| Dong, H | 1 |
| Hammock, BD | 1 |
| Pinkerton, KE | 1 |
| Michalski, J | 1 |
| Kanaji, N | 1 |
| Liu, X | 1 |
| Nogel, S | 1 |
| Wang, X | 1 |
| Basma, H | 1 |
| Nakanishi, M | 1 |
| Sato, T | 1 |
| Gunji, Y | 1 |
| Fahrid, M | 1 |
| Nelson, A | 1 |
| Muller, KC | 1 |
| Holz, O | 1 |
| Magnussen, H | 1 |
| Rabe, KF | 1 |
| Toews, ML | 1 |
| Rennard, SI | 1 |
| Devillier, P | 1 |
| Vignola, AM | 1 |
| Ariga, M | 1 |
| Neitzert, B | 1 |
| Nakae, S | 1 |
| Mottin, G | 1 |
| Bertrand, C | 3 |
| Pruniaux, MP | 3 |
| Jin, SL | 1 |
| Conti, M | 1 |
| Ouagued, M | 1 |
| Martin-Chouly, CA | 2 |
| Brinchault, G | 1 |
| Leportier-Comoy, C | 1 |
| Depincé, A | 2 |
| Lagente, V | 2 |
| Belleguic, C | 2 |
| Gouault, N | 1 |
| Pinel, B | 1 |
| Cupif, JF | 1 |
| David, M | 1 |
| Jones, NA | 1 |
| Leport, M | 1 |
| Holand, T | 1 |
| Vos, T | 1 |
| Morgan, M | 1 |
| Fink, M | 1 |
| Berthelier, C | 1 |
| O'Connor, BJ | 1 |
| Page, CP | 2 |
| Nénan, S | 1 |
| Planquois, JM | 1 |
| Hitier, S | 1 |
| Berna, P | 1 |
| Bertrand, CP | 1 |
| Boichot, E | 1 |
| Edwards, MR | 1 |
| Haas, J | 1 |
| Panettieri, RA | 1 |
| Johnson, M | 1 |
| Johnston, SL | 1 |
| Rickards, KJ | 1 |
| Lees, P | 1 |
| Cunningham, FM | 1 |
| Toward, TJ | 1 |
| Broadley, KJ | 1 |
3 reviews available for rolipram and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Topics: Asthma; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chr | 2008 |
[Physiopathology of COPD: choosing the right therapeutic targets].
Topics: Adrenal Cortex Hormones; Aged; Albuterol; Animals; Bacterial Infections; Bronchodilator Agents; Carb | 2003 |
PDE4 inhibitors in COPD--a more selective approach to treatment.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Benzamides; Bronchodilator Agents; Carboxylic A | 2004 |
1 trial available for rolipram and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Azepines; Carboxylic Acids; Cyclic Nucleotide Phosphodie | 2005 |
14 other studies available for rolipram and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
Topics: Animals; Asthma; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Models, Animal; Drug Design; | 2017 |
Synthesis and bioactivity of 3,5-dimethylpyrazole derivatives as potential PDE4 inhibitors.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Inhibitory Concentration 50; Mice; Phosphodiesterase | 2018 |
Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease.
Topics: Aminopyridines; Benzamides; Calcium; CD11b Antigen; Chemokine CXCL1; Chemotaxis, Leukocyte; Cyclic A | 2019 |
The absence of mrp4 has no effect on the recruitment of neutrophils and eosinophils into the lung after LPS, cigarette smoke or allergen challenge.
Topics: Adenosine; Allergens; Animals; Asthma; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP- | 2013 |
Hesperetin-7,3'-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio.
Topics: Animals; Asthma; Binding Sites; Blood Cell Count; Bronchial Hyperreactivity; Bronchoalveolar Lavage | 2011 |
Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease.
Topics: Animals; Benzoates; Body Weight; Bronchoalveolar Lavage Fluid; Cytokines; Enzyme Inhibitors; Epoxide | 2012 |
Attenuation of inhibitory prostaglandin E2 signaling in human lung fibroblasts is mediated by phosphodiesterase 4.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Aminopyridines; Benzamides; Cells, Cultured; Chemota | 2012 |
Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cell Adhesion; Chemokines; Chemotaxis, Leukocyte; Cycl | 2004 |
Synthesis and potential anti-inflammatory activity of some tetrahydrophthalazinones.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Anti-Inflammatory Agents, Non-Steroidal; Benzam | 2004 |
Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Aged; Asthma; Benzamides; CD4-Positive T-Lymphocytes; CD | 2007 |
Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat.
Topics: Animals; Bronchoalveolar Lavage Fluid; Chemokines; Cytokines; Dexamethasone; Enzyme Inhibitors; Gluc | 2007 |
Corticosteroids and beta2 agonists differentially regulate rhinovirus-induced interleukin-6 via distinct Cis-acting elements.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Inflammatory Agen | 2007 |
Phosphodiesterase activity in neutrophils from horses with chronic obstructive pulmonary disease.
Topics: Animals; Dose-Response Relationship, Immunologic; Guanidines; Horse Diseases; Horses; Isoenzymes; Ne | 2000 |
Airway function, oedema, cell infiltration and nitric oxide generation in conscious ozone-exposed guinea-pigs: effects of dexamethasone and rolipram.
Topics: Animals; Dexamethasone; Guinea Pigs; Male; Neutrophil Infiltration; Nitric Oxide; Oxidative Stress; | 2002 |